Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blind, crossover TQT study effects of nebulized ensifentrine on measures of cardiac conduction compared with placebo in healthy volunteers

Next Previous
X
Search
Trial Profile

Randomized, double-blind, crossover TQT study effects of nebulized ensifentrine on measures of cardiac conduction compared with placebo in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ensifentrine (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors Verona Pharma

    • Most Recent Events

    • 09 May 2022 According to a Verona Pharma media release, data from this trial will be published at the American Thoracic Society International Conference (ATS) 2022
    • 21 Dec 2021 New trial record
    • 16 Dec 2021 According to a Verona Pharma media release, as per USFDA one study was required to support most New Drug Applications for potential new medications. The protocol of this study was reviewed by the FDA prior to commencing the study, and these results will support the planned submission for ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top